About Rhythm Biotherapeutics Inc.
Developing first-in-class extracellular vesicle therapeutics targeting the underlying causes of atrial fibrillation.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Ottawa, Ontario
- Founded
- 2022
- Company type
- Privately Held
Rhythm Biotherapeutics Inc. (RBI) is a pre-clinical spinout of the University of Ottawa Heart Institute, founded in November 2022 by Darryl Davis, a cardiac electrophysiologist pioneering novel therapies to prevent and cure atrial fibrillation (AF). The company has developed a patent pending exosome therapy that, in animal studies, has proven to effectively prevent postoperative atrial fibrillation (POAF). RBI’s therapy uniquely addresses atrial inflammation and fibrosis, the fundamental physiological mechanism driving POAF. RBI is currently seeking investors who will accelerate achieving its next milestones. The obtainable market in North America and Europe for POAF therapy is over US$2B per year and growing.
Company locations
40 Ruskin Street, Ottawa, Ontario K1Y 4W7 , CA
Locations listed on the company profile. These may include offices outside Canada, and not every location is hiring.
On LinkedIn
- Followers
- 483
- People linked to this company
- 6
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.